German healthcare and materials company Merck KGaA (NSE:PROR) announced on Monday that it has agreed to acquire U.S.-based ...

Merck KGaA entered into a definitive agreement to acquire U.S. biopharmaceutical company SpringWorks Therapeutics in a deal ...

Merck KGaA agreed to buy SpringWorks Therapeutics Inc., a maker of medicines for cancer and rare diseases, to boost its ...

Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of ...

Merck KGaA, Darmstadt, Germany (DAX: MRK), a leading science and technology company, and SpringWorks Therapeutics, Inc.